Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma

Toripalimab as a novel PD-1 inhibitor has presented its promising efficacy in patients who developed chemo-refractory carcinomas, whereas no study has ever investigated the effectiveness of toripalimab in chemo-resistant choriocarcinoma. Here we reported the effectiveness and safety data of 4 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaomei, Li, Xiuqin, Qu, Hui, Zhang, Shiyue, Zhang, Ruizhe, Du, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047865/
https://www.ncbi.nlm.nih.gov/pubmed/35494052
http://dx.doi.org/10.3389/fonc.2022.815917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047865/
https://www.ncbi.nlm.nih.gov/pubmed/35494052
http://dx.doi.org/10.3389/fonc.2022.815917

Ejemplares similares